Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab
Phase 1/2RecruitingDevelopment Stage
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Jun 22, 2021 → May 30, 2029
About Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab
Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab is a phase 1/2 stage product being developed by Roche for Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04802759. Target conditions include Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04802759 | Phase 1/2 | Recruiting |
Competing Products
10 competing products in Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin Mesylate | Eisai | Pre-clinical | 26 |
| Premetrexed (Alimta) + Carboplatin | Eli Lilly | Phase 1 | 29 |
| Fulvestrant + Capivasertib + Placebo | AstraZeneca | Phase 3 | 44 |
| Selumetinib | AstraZeneca | Pre-clinical | 26 |
| Tomudex | AstraZeneca | Phase 2 | 35 |
| Cisplatin + Gemcitabine + Selumetinib | AstraZeneca | Phase 1 | 21 |
| Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | AstraZeneca | Phase 3 | 47 |
| Drug (including placebo) | Merck | Phase 1 | 21 |
| BEZ235 + Paclitaxel | Novartis | Phase 1/2 | 24 |
| dacomitinib hydrate | Pfizer | Pre-clinical | 26 |